Institute for Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.
J Biol Chem. 2010 Apr 9;285(15):11178-87. doi: 10.1074/jbc.M109.092973. Epub 2010 Jan 22.
HSAN1 is an inherited neuropathy found to be associated with several missense mutations in the SPTLC1 subunit of serine palmitoyltransferase (SPT). SPT catalyzes the condensation of serine and palmitoyl-CoA, the initial step in the de novo synthesis of sphingolipids. Here we show that the HSAN1 mutations induce a shift in the substrate specificity of SPT, which leads to the formation of the two atypical deoxy-sphingoid bases (DSBs) 1-deoxy-sphinganine and 1-deoxymethyl-sphinganine. Both metabolites lack the C(1) hydroxyl group of sphinganine and can therefore neither be converted to complex sphingolipids nor degraded. Consequently, they accumulate in the cell, as demonstrated in HEK293 cells overexpressing mutant SPTLC1 and lymphoblasts of HSAN1 patients. Elevated DSB levels were also found in the plasma of HSAN1 patients and confirmed in three groups of HSAN1 patients with different SPTLC1 mutations. The DSBs show pronounced neurotoxic effects on neurite formation in cultured sensory neurons. The neurotoxicity co-occurs with a disturbed neurofilament structure in neurites when cultured in the presence of DSBs. Based on these observations, we conclude that HSAN1 is caused by a gain of function mutation, which results in the formation of two atypical and neurotoxic sphingolipid metabolites.
HSAN1 是一种遗传性周围神经病,与丝氨酸棕榈酰转移酶(SPT)的 SPTLC1 亚基的几个错义突变有关。SPT 催化丝氨酸和棕榈酰-CoA 的缩合,这是鞘脂从头合成的初始步骤。在这里,我们表明 HSAN1 突变诱导 SPT 的底物特异性发生转变,导致两种非典型的去氧鞘氨醇碱基(DSB)1-脱氧鞘氨醇和 1-去甲甲基鞘氨醇的形成。这两种代谢物都缺乏鞘氨醇的 C(1)羟基,因此既不能转化为复杂的鞘脂,也不能降解。因此,它们在细胞中积累,正如在过表达突变 SPTLC1 的 HEK293 细胞和 HSAN1 患者的淋巴母细胞中所证明的那样。HSAN1 患者的血浆中也发现了升高的 DSB 水平,并在三组具有不同 SPTLC1 突变的 HSAN1 患者中得到了证实。DSB 对培养的感觉神经元中的轴突形成表现出明显的神经毒性作用。当在 DSB 存在的情况下培养时,神经毒性与神经丝结构的紊乱同时发生。基于这些观察结果,我们得出结论,HSAN1 是由功能获得性突变引起的,导致形成两种非典型和神经毒性的鞘脂代谢物。